The global pneumonia therapeutics market was valued at $12,293.9 million in 2020, and is projected to reach $25,546.8 million by 2030, registering a CAGR of 8.5% from 2021 to 2030.
Pneumonia is an infection that affects the lower respiratory tract. Furthermore, pneumonia is characterized by symptoms such as short breathing, fever, chest pain, nausea, and vomiting. In pneumonia, the air sacs of lungs called as alveoli are filled with fluid or pus that cause inflammation. It is majorly caused by microorganisms such as fungi, bacteria, virus, and parasites, and mostly affects people with weakened immune systems, and is common in children and older people.
The growth of the global pneumonia therapeutics market is majorly driven by rise in incidence of pneumonia. In addition, increase in prevalence community-acquired pneumonia is expected to propel the industry growth during the forecast period. Furthermore, increase in product launches after FDA approval is expected to help the industry gain maximum revenue. In addition, surge in clinical trials for the R&D of for development of vaccines and drug molecules is projected to help the industry grow in the next few years. However, implementation of stringent regulations for vaccines and drugs hinders the market growth.
The global pneumonia therapeutics market is segmented into therapeutics, distribution channel, age group, and region. On the basis of therapeutics, the market is categorized into prevention vaccines, and treatment drugs. By distribution channel, it is classified into hospitals, pharmaceutical stores, and others. Depending on age group, it is segregated into pediatric, adult, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Pneumonia is an infection that affects the lower respiratory tract. Furthermore, pneumonia is characterized by symptoms such as short breathing, fever, chest pain, nausea, and vomiting. In pneumonia, the air sacs of lungs called as alveoli are filled with fluid or pus that cause inflammation. It is majorly caused by microorganisms such as fungi, bacteria, virus, and parasites, and mostly affects people with weakened immune systems, and is common in children and older people.
The growth of the global pneumonia therapeutics market is majorly driven by rise in incidence of pneumonia. In addition, increase in prevalence community-acquired pneumonia is expected to propel the industry growth during the forecast period. Furthermore, increase in product launches after FDA approval is expected to help the industry gain maximum revenue. In addition, surge in clinical trials for the R&D of for development of vaccines and drug molecules is projected to help the industry grow in the next few years. However, implementation of stringent regulations for vaccines and drugs hinders the market growth.
The global pneumonia therapeutics market is segmented into therapeutics, distribution channel, age group, and region. On the basis of therapeutics, the market is categorized into prevention vaccines, and treatment drugs. By distribution channel, it is classified into hospitals, pharmaceutical stores, and others. Depending on age group, it is segregated into pediatric, adult, and geriatric. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Therapeutics
- Prevention Vaccines
- Treatment Drugs
By Distribution Channel
- Hospitals
- Pharmaceutical Stores
- Others
By Age Group
- Pediatric
- Adult
- Geriatric
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Abbott Laboratories
- Bayer AG
- Eli Lilly & Company
- Glaxosmithkline Plc.
- Lupin Pharmaceuticals, Inc.
- Merck KGAA
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Teva Pharmaceuticals Industries Limited
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of pneumonia
3.5.1.2. Upsurge in geriatric population with weaker immune systems
3.5.1.3. Increase in incidence and spending for community-acquired pneumonia
3.5.1.4. Surge in number of product launches
3.5.2. Restraint
3.5.2.1. High price of pneumonia therapeutics
3.5.3. Opportunity
3.5.3.1. Outbreak of novel viruses attacking respiratory system
3.5.4. Impact analysis
3.6. COVID-19 Impact analysis on the pneumonia therapeutics market
CHAPTER 4: PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS4.1. Overview
4.1.1. Market size and forecast
4.2. Prevention vaccines
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.2.4. Market analysis, by distribution channel
4.3. Treatment drugs
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.3.4. Market analysis, by distribution channel
CHAPTER 5: PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL5.1. Overview
5.1.1. Market size and forecast
5.2. Hospitals
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Pharmaceutical stores
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
CHAPTER 6: PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP6.1. Overview
6.1.1. Market size and forecast
6.2. Pediatric
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Adult
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Geriatric
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: PNEUMONIA THERAPEUTICS MARKET, BY REGION7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. pneumonia therapeutics market, by therapeutics
7.2.2.1.2. U.S. pneumonia therapeutics market, by distribution channel
7.2.2.1.3. U.S. pneumonia therapeutics market, by age group
7.2.2.2. Canada
7.2.2.2.1. Canada pneumonia therapeutics market, by therapeutics
7.2.2.2.2. Canada pneumonia therapeutics market, by distribution channel
7.2.2.2.3. Canada pneumonia therapeutics market, by age group
7.2.2.3. Mexico
7.2.2.3.1. Mexico pneumonia therapeutics market, by therapeutics
7.2.2.3.2. Mexico pneumonia therapeutics market, by distribution channel
7.2.2.3.3. Mexico pneumonia therapeutics market, by age group
7.2.3. North America market size and forecast, by therapeutics
7.2.4. North America market size and forecast, by distribution channel
7.2.5. North America market size and forecast, by age group
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. UK
7.3.2.1.1. UK pneumonia therapeutics market, by therapeutics
7.3.2.1.2. UK pneumonia therapeutics market, by distribution channel
7.3.2.1.3. UK pneumonia therapeutics market, by age group
7.3.2.2. Germany
7.3.2.2.1. Germany pneumonia therapeutics market, by therapeutics
7.3.2.2.2. Germany pneumonia therapeutics market, by distribution channel
7.3.2.2.3. Germany pneumonia therapeutics market, by age group
7.3.2.3. France
7.3.2.3.1. France pneumonia therapeutics market, by therapeutics
7.3.2.3.2. France pneumonia therapeutics market, by distribution channel
7.3.2.3.3. France pneumonia therapeutics market, by age group
7.3.2.4. Italy
7.3.2.4.1. Italy pneumonia therapeutics market, by therapeutics
7.3.2.4.2. Italy pneumonia therapeutics market, by distribution channel
7.3.2.4.3. Italy pneumonia therapeutics market, by age group
7.3.2.5. Spain
7.3.2.5.1. Spain pneumonia therapeutics market, by therapeutics
7.3.2.5.2. Spain pneumonia therapeutics market, by distribution channel
7.3.2.5.3. Spain pneumonia therapeutics market, by age group
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe pneumonia therapeutics market, by therapeutics
7.3.2.6.2. Rest of Europe pneumonia therapeutics market, by distribution channel
7.3.2.6.3. Rest of Europe pneumonia therapeutics market, by age group
7.3.3. Europe market size and forecast, by therapeutics
7.3.4. Europe market size and forecast, by distribution channel
7.3.5. Europe market size and forecast, by age group
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. India
7.4.2.1.1. India pneumonia therapeutics market, by therapeutics
7.4.2.1.2. India pneumonia therapeutics market, by distribution channel
7.4.2.1.3. India pneumonia therapeutics market, by age group
7.4.2.2. China
7.4.2.2.1. China pneumonia therapeutics market, by therapeutics
7.4.2.2.2. China pneumonia therapeutics market, by distribution channel
7.4.2.2.3. China pneumonia therapeutics market, by age group
7.4.2.3. Japan
7.4.2.3.1. Japan pneumonia therapeutics market, by therapeutics
7.4.2.3.2. Japan pneumonia therapeutics market, by distribution channel
7.4.2.3.3. Japan pneumonia therapeutics market, by age group
7.4.2.4. Australia
7.4.2.4.1. Australia pneumonia therapeutics market, by therapeutics
7.4.2.4.2. Australia pneumonia therapeutics market, by distribution channel
7.4.2.4.3. Australia pneumonia therapeutics market, by age group
7.4.2.5. South Korea
7.4.2.5.1. South Korea pneumonia therapeutics market, by therapeutics
7.4.2.5.2. South Korea pneumonia therapeutics market, by distribution channel
7.4.2.5.3. South Korea pneumonia therapeutics market, by age group
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific pneumonia therapeutics market, by therapeutics
7.4.2.6.2. Rest of Asia-Pacific pneumonia therapeutics market, by distribution channel
7.4.2.6.3. Rest of Asia-Pacific pneumonia therapeutics market, by age group
7.4.3. Asia-Pacific market size and forecast, by therapeutics
7.4.4. Asia-Pacific market size and forecast, by distribution channel
7.4.5. Asia-Pacific market size and forecast, by age group
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil pneumonia therapeutics market, by therapeutics
7.5.2.1.2. Brazil pneumonia therapeutics market, by distribution channel
7.5.2.1.3. Brazil pneumonia therapeutics market, by age group
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia pneumonia therapeutics market, by therapeutics
7.5.2.2.2. Saudi Arabia pneumonia therapeutics market, by distribution channel
7.5.2.2.3. Saudi Arabia pneumonia therapeutics market, by age group
7.5.2.3. South Africa
7.5.2.3.1. South Africa pneumonia therapeutics market, by therapeutics
7.5.2.3.2. South Africa pneumonia therapeutics market, by distribution channel
7.5.2.3.3. South Africa pneumonia therapeutics market, by age group
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA pneumonia therapeutics market, by therapeutics
7.5.2.4.2. Rest of LAMEA pneumonia therapeutics market, by distribution channel
7.5.2.4.3. Rest of LAMEA pneumonia therapeutics market, by age group
7.5.3. LAMEA market size and forecast, by therapeutics
7.5.4. LAMEA market size and forecast, by distribution channel
7.5.5. LAMEA market size and forecast, by age group
CHAPTER 8: COMPANY PROFILES8.1. ABBOTT LABORATORIES
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. ELI LILLY & COMPANY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline PLC
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. LUPIN PHARMACEUTICALS, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. MERCK KGAA
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NOVARTIS AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. PFIZER, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. SANOFI S. A.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TEVA PHARMACEUTICALS INDUSTRIES LIMITED
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List of Tables
TABLE 01. GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 02. PNEUMONIA THERAPEUTICS MARKET FOR PREVENTION VACCINES, BY REGION, 2020-2030 ($MILLION)
TABLE 03. PNEUMONIA THERAPEUTICS MARKET FOR PREVENTION VACCINES, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 04. PNEUMONIA THERAPEUTICS MARKET FOR TREATMENT DRUGS, BY REGION, 2020-2030 ($MILLION)
TABLE 05. PNEUMONIA THERAPEUTICS MARKET FOR TREATMENT DRUGS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 06. GLOBAL PNEUMONIA THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 07. PNEUMONIA THERAPEUTICS MARKET FOR HOSPITALS, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 08. PNEUMONIA THERAPEUTICS MARKET FOR PHARMACEUTICAL STORES, BY DISTRIBUTION CHANNEL 2020-2030 ($MILLION)
TABLE 09. PNEUMONIA THERAPEUTICS MARKET, OTHERS, BY DISTRIBUTION CHANNEL 2020-2030 ($MILLION)
TABLE 10. PNEUMONIA THERAPEUTICS MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 11. PNEUMONIA THERAPEUTICS MARKET FOR PEDIATRIC, BY REGION, 2020-2030 ($MILLION)
TABLE 12. PNEUMONIA THERAPEUTICS MARKET FOR ADULT, BY REGION, 2020-2030 ($MILLION)
TABLE 13. PNEUMONIA THERAPEUTICS MARKET FOR GERIATRIC, BY REGION, 2020-2030 ($MILLION)
TABLE 14. PNEUMONIA THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 16. U.S. PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 17. U.S. PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 18. U.S. PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 19. CANADA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 20. CANADA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 21. CANADA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 22. MEXICO PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 23. MEXICO PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 24. MEXICO PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 25. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 26. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 27. NORTH AMERICA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 28. EUROPE PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 29. UK PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 30. UK PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 31. UK PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 32. GERMANY PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 33. GERMANY PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 34. GERMANY PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 35. FRANCE PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 36. FRANCE PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 37. FRANCE PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 38. ITALY PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 39. ITALY PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 40. ITALY PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 41. SPAIN PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 42. SPAIN PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 43. SPAIN PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 44. REST OF EUROPE PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 45. REST OF EUROPE PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 46. REST OF EUROPE PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 47. EUROPE PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 48. EUROPE PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 49. EUROPE PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 50. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 51. INDIA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 52. INDIA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 53. INDIA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 54. CHINA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 55. CHINA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 56. CHINA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 57. JAPAN PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 58. JAPAN PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 59. JAPAN PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 61. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 62. AUSTRALIA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 63. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 64. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 65. SOUTH KOREA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 69. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 70. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 71. ASIA-PACIFIC PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 72. LAMEA PNEUMONIA THERAPEUTICS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 73. BRAZIL PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 74. BRAZIL PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 75. BRAZIL PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 76. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 77. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 78. SAUDI ARABIA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 79. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 80. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 81. SOUTH AFRICA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 82. REST OF LAMEA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 83. REST OF LAMEA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 84. REST OF LAMEA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 85. LAMEA PNEUMONIA THERAPEUTICS MARKET, BY THERAPEUTICS, 2020-2030 ($MILLION)
TABLE 86. LAMEA PNEUMONIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 87. LAMEA PNEUMONIA THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 88. ABBOTT: COMPANY SNAPSHOT
TABLE 89. ABBOTT: PRODUCT SEGMENTS
TABLE 90. ABBOTT: PRODUCT PORTFOLIO
TABLE 91. ABBOTT: KEY DEVELOPMENTS
TABLE 92. BAYER: COMPANY SNAPSHOT
TABLE 93. BAYER: OPERATING SEGMENTS
TABLE 94. BAYER: PRODUCT PORTFOLIO
TABLE 95. ELI LILLY & COMPANY: COMPANY SNAPSHOT
TABLE 96. ELI LILLY & COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 97. ELI LILLY & COMPANY: PRODUCT PORTFOLIO
TABLE 98. GLAXO: COMPANY SNAPSHOT
TABLE 99. GLAXO: OPERATING SEGMENTS
TABLE 100. GLAXO: PRODUCT PORTFOLIO
TABLE 101. LUPIN: COMPANY SNAPSHOT
TABLE 102. LUPIN: OPERATING SEGMENTS
TABLE 103. LUPIN: PRODUCT PORTFOLIO
TABLE 104. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. MERCK: COMPANY SNAPSHOT
TABLE 106. MERCK: OPERATING SEGMENTS
TABLE 107. MERCK: PRODUCT PORTFOLIO
TABLE 108. MERCK: KEY DEVELOPMENTS
TABLE 109. NOVARTIS: COMPANY SNAPSHOT
TABLE 110. NOVARTIS: OPERATING SEGMENT
TABLE 111. NOVARTIS: PRODUCT PORTFOLIO
TABLE 112. NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113. PFIZER: COMPANY SNAPSHOT
TABLE 114. PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 115. PFIZER: PRODUCT PORTFOLIO
TABLE 116. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. SANOFI: COMPANY SNAPSHOT
TABLE 118. SANOFI: OPERATING BUSINESS SEGMENTS
TABLE 119. SANOFI: PRODUCT PORTFOLIO
TABLE 120. TEVA PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 121. TEVA PHARMACEUTICALS: OPERATING SEGMENTS
TABLE 122. TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. PNEUMONIA THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. HIGH INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR PREVENTION VACCINES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR TREATMENT DRUGS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR PHARMACEUTICAL STORES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET FOR PEDIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET, ADULT, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF PNEUMONIA THERAPEUTICS MARKET, GERIATRIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. ABBOTT: NET SALES, 2018-2020 ($MILLION)
FIGURE 22. ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23. ABBOTT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 24. BAYER: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. BAYER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26. BAYER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 27. ELI LILLY & COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 28. ELI LILLY & COMPANY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29. GLAXO:NET SALES,2018-2020 ($MILLION)
FIGURE 30. GLAXO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31. GLAXO: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32. LUPIN: NET SALES, 2018-2020 ($MILLION)
FIGURE 33. LUPIN: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 35. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36. MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37. NOVARTIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 38. NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39. NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40. PFIZER: NET SALES, 2018-2020 ($MILLION
FIGURE 41. PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42. SANOFI: REVENUE, 2018-2020 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45. TEVA PHARMACEUTICALS: NET SALES, 2018-2020 ($MILLION)
FIGURE 46. TEVA PHARMACEUTICALS: REVENUE SHARE BY SEGMENT, 2020 (%)
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Eli Lilly & Company
- Glaxosmithkline PLC.
- Lupin Pharmaceuticals Inc.
- Merck KGAA
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceuticals Industries Limited.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 208 |
| Published | August 2021 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 12293.9 million |
| Forecasted Market Value ( USD | $ 25546.8 million |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
